Navigation Links
CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation
Date:5/21/2008

New Data Underscore the Utility of CAPHOSOL in Treating Oral Mucositis

PRINCETON, N.J., May 21 /PRNewswire/ -- New data show that CAPHOSOL(R) (http://www.caphosol.com), an advanced electrolyte solution, relieves painful oral mucositis (OM) and improves quality of life for cancer patients undergoing chemotherapy and radiation therapy. These data were reported in two separate presentations last week at the 33rd Annual Congress of the Oncology Nursing Society (ONS) in Philadelphia. These data confirm that CAPHOSOL is a useful tool to help oncology nurses and other healthcare professionals in the management of OM and related symptoms, particularly in patients with head and neck cancer and those receiving chemotherapy.

One of the two abstracts including this data, ONS Abstract #2757, "Supersaturated Electrolyte Oral Rinse Aids Quality of Life for Head/Neck Chemoradiation Patients" (Haas, ML), was selected by an ONS Expert Panel as one of the Top Ten Best Supportive Care abstracts at the ONS 2008 Congress.

"Oral mucositis is a painful, common side effect experienced by cancer patients receiving chemotherapy and radiation therapy," commented principal investigator Marilyn L. Haas, PhD, RN, CNS, ANP-C, Nurse Practitioner, Mountain Radiation Oncology, Asheville, N.C. "As layers of epithelial cells in the oral cavity (cells lining the surface of the throat and esophagus) are eroded during therapy, patients often experience severe pain, are more prone to infection and have difficulty eating and swallowing. Our research concludes that CAPHOSOL, a supersaturated electrolyte oral rinse, should be introduced early in the course of cancer therapy for patients at high risk of oral mucositis because it minimizes the onset and severity of symptoms."

The rate of severe oral mucositis (NCI Clinical OM Grade 3-4) reported by head and neck cancer patients using CAPHOSOL in this study was 11% (Grade 3) an
'/>"/>

SOURCE EUSA Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile
2. Oxygen Relieves IBS and Constipation Symptoms in New Clinical Studies
3. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
6. AviaraDx Confirms That Combination of Two Molecular Biomarkers Improves Prediction of Disease Recurrence in Early Stage Breast Cancer Patients
7. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
8. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
9. Gene Therapy Improves Vision in Patients with Congenital Retinal Disease
10. SuperGens DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
11. Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Thirty-six million Americans suffer from hearing ... – National Hearing Month – more than 28 million ... on the sounds of spring, like birds singing and ... ensure that you won,t be among those missing out ... Inc. offers practical advice: Take action if ...
(Date:5/4/2015)... 4, 2015 Southfield Capital, a ... announced today that it completed a dividend ... specializes in the development and multi-channel deployment ... and biotechnology industries. Through the ... half of their invested capital and secured ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
Breaking Medicine Technology:It's Better Hearing Month 2Southfield Capital and BioPharm Communications Announce Dividend Recapitalization 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5
... , FRANKLIN LAKES, N.J. , ... BDX ), a leading global medical technology company, is increasing ... Haiti earthquake relief efforts from the $500,000 ... in market value of critical medical supplies.  This additional commitment will ...
... , Jan. 27 CardioGenics Holdings Inc. (OTC ... the in-vitro diagnostics segment of the Point-Of-Care (POC) diagnostic market, ... self-metering cartridge for its POC diagnostic device, the QL Care ... the self-metering cartridge. , Dr. Yahia Gawad , CEO ...
Cached Medicine Technology:BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 2BD Increases Haiti Relief Fund to Include $5 Million in Product Donations 3CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 2CardioGenics Announces Completion of Cartridge Design for QL Care Analyzer 3
(Date:5/4/2015)... 2015 “ LiveSchool ” was featured ... takes a look at the latest and coolest applications ... Toohey, the host of AppWatch and technology expert, conducted ... application allows teachers to reward students with good behavior. ... especially in the classroom. And the good people ...
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
(Date:5/4/2015)... The Lymphoma Research Foundation (LRF) – the ... lymphoma research and serving the lymphoma community through a ... services – is set to host its annual Ace ... Orange, NJ on June 1, 2015. Since 2010, the ... through LRF. , This year, the Lymphoma Research Foundation ...
(Date:5/4/2015)... May 04, 2015 The American Telemedicine ... state policy reports which identify gaps in coverage and ... ATA issued the State Telemedicine Gaps Reports last September, ... their laws and regulations impact healthcare delivery in their ... result of state actions across the nation, ATA reevaluated ...
(Date:5/4/2015)... May 04, 2015 The opportunity for children ... life are the motivating forces behind The Fairy Godmother Next ... and author Amy L. Stark. , The inspiration for the ... next door comes from Stark’s desire to be a fairy ... a fairy godmother to my neighbors’ children since they were ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Lymphoma Research Foundation Set to Host Annual Ace Lymphoma Luncheon at Mayfair Farms in West Orange, NJ 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 2Health News:American Telemedicine Association Delivers New State Report Cards on Telemedicine 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... Ustekinumab injections every 3 months a more convenient ... News) -- The drug ustekinumab has been shown to ... moderate-to-severe psoriasis in two studies published in this week,s ... by binding to two interleukins, proteins produced by the ...
... leadership in proposing prescription,drug marketing reform and transparency, ... believes,New York has a paramount interest in passing ... undue influence that,pharmaceutical companies have over prescribing decisions ... treatment they receive., The reforms include banning ...
... worldwide cancer incidence, researchers at the Moores Cancer Center ... Department of Family and Preventive Medicine have shown a ... ultraviolet B (UVB), and breast cancer. , UVB ... This form of vitamin D also is available through ...
... May 15 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... March 31, 2008. Pharmasset reported a net loss ... per share for the,quarter ended March 31, 2008, ...
... The following is a,statement from Larry Minnix, President ... Aging:, "Today,s GAO report points out yet again ... of nursing homes in this country. If,we want to ... need to,rethink our approach from the bottom up., ...
... Theranostics Health (THX) today,announced that it ... agreement with Duke University. This relationship will,provide ... technologies: Laser,Capture Microdissection (LCM) and Reverse Phase ... technologies provides a powerful,mechanism to accurately and ...
Cached Medicine News:Health News:Drug Works Well for Moderate-to-Severe Psoriasis 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2Health News:UCSD researchers show link between vitamin D status, breast cancer 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8Health News:Theranostics Health Signs Research Collaboration Agreement 2
Plus cylinders only trial lens set....
Trial Lens Sets....
70 discs to investigate acquired color deficiency. Quantifies neutral zone characteristics of dyschromatopsia and evaluates the relative luminance....
... test (P/N LD15C) include a durable laminated ... P/N LD15C also includes a Plexiglas Case ... for the test subjects fingers ( to ... discs). Beware that these finger cots are ...
Medicine Products: